NYU Langone Health Embarks on a New Leadership Journey with Dr. Alec C. Kimmelman
The Passing of the Torch at NYU Langone
In a significant leadership transition at NYU Langone Health, the esteemed Alec C. Kimmelman, MD, PhD, has been named as the new CEO and Dean of NYU Grossman School of Medicine. Known for his groundbreaking work in radiation oncology, Dr. Kimmelman will officially take the helm on September 1, succeeding the retiring Robert I. Grossman, MD. His appointment marks the beginning of an exciting new chapter for the institution.
Building on a Strong Foundation
Dr. Robert I. Grossman’s 18-year tenure has seen NYU Langone Health evolve from a modest regional hospital into a leading academic health system with remarkable achievements, including $14.2 billion in revenues and top national rankings. As the new leader, Dr. Kimmelman is set to continue this momentum and build on Grossman’s legacy, as confirmed in a unanimous vote by the Board of Trustees.
An Opportunity for Growth and Innovation
Excitement surrounds Dr. Kimmelman’s appointment, as emphasized by Kenneth Langone, chair of the NYU Langone Board of Trustees, who expressed confidence in Dr. Kimmelman’s talent and leadership abilities to steer the institution toward further innovation and impact. NYU Langone Health
Dr. Kimmelman’s Vision for the Future
Expressing his excitement, Dr. Kimmelman states, “I am humbled to continue the legacy of innovation and excellence at NYU Langone. Our goal is to achieve the best outcomes in patient care, education, and science.” His tenure brings opportunities for expansion and innovation, such as the recent establishment of the Center for Molecular Oncology, which revolutionizes cancer treatment with personalized care options.
A Proven Leader in Medicine
Dr. Kimmelman’s career at NYU Langone highlights significant contributions, particularly in molecular oncology, where he has established himself as a leader through his research. Under his direction, Perlmutter Cancer Center has become a pioneer in cancer treatment, leveraging molecular data to tailor therapies to individual patients.
Honors and Accomplishments
Dr. Kimmelman is not only a published researcher with over 100 articles but also a recipient of numerous awards, including the Outstanding Investigator Award from the National Cancer Institute. His work in pancreatic cancer research positions him as a trailblazer in the field, promising to bring a wealth of expertise and innovation to NYU Langone Health.
Looking Ahead
With Dr. Kimmelman at the helm, NYU Langone Health stands poised to continue its trajectory of excellence and innovation, ensuring top-tier medical services and research that keep it at the forefront of healthcare in the nation. The future holds promising advancements in patient care and medical education under his leadership.
